APA (7th ed.) Citation

ZS, C., G, K., K, O., N, J., J, S., M, P., . . . H, O. (2018). Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. The Journal of experimental medicine, 215(1), 141. https://doi.org/10.1084/jem.20171046

Chicago Style (17th ed.) Citation

ZS, Chheda, et al. "Novel and Shared Neoantigen Derived from Histone 3 Variant H3.3K27M Mutation for Glioma T Cell Therapy." The Journal of Experimental Medicine 215, no. 1 (2018): 141. https://doi.org/10.1084/jem.20171046.

MLA (9th ed.) Citation

ZS, Chheda, et al. "Novel and Shared Neoantigen Derived from Histone 3 Variant H3.3K27M Mutation for Glioma T Cell Therapy." The Journal of Experimental Medicine, vol. 215, no. 1, 2018, p. 141, https://doi.org/10.1084/jem.20171046.